Further, it is still not clear why FGF21 administration tends to improve metabolic endpoints, yet FGF21 levels are paradoxically increased with metabolic conditions such as obesity, type 2 diabetes, and cardiovascular disease. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.